<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26875173</PMID><DateCompleted><Year>2016</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1559-1166</ISSN><JournalIssue CitedMedium="Internet"><Volume>58</Volume><Issue>3</Issue><PubDate><Year>2016</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of molecular neuroscience : MN</Title><ISOAbbreviation>J Mol Neurosci</ISOAbbreviation></Journal><ArticleTitle>Introduction to the Special Issue on Spinal and Bulbar Muscular Atrophy.</ArticleTitle><Pagination><StartPage>313</StartPage><EndPage>316</EndPage><MedlinePgn>313-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12031-016-0720-0</ELocationID><Abstract><AbstractText>This special issue is dedicated to spinal and bulbar muscular atrophy (SBMA) and is based on the conference sponsored by the European Neuromuscular Centre (ENMC) held in March 2015. SBMA, also known as Kennedy's disease, is a neurodegenerative disease caused by an expansion of a repeat of the trinucleotide CAG encoding glutamine in the gene encoding androgen receptor (AR). Expansion of polyglutamine in the AR results in selective lower motor neuron degeneration and skeletal muscle atrophy. SBMA belongs to the family of polyglutamine diseases, which also includes Huntington's disease, dentatorubral-pallidoluysian atrophy, and spinocerebellar ataxia (SCA) types 1, 2, 3, 6, 7, and 17. Within the family of polyglutamine diseases, SBMA is unique in its gender-specificity, with full disease manifestation restricted to males. Since the disease is ligand (androgen)-dependent, SBMA manifests primarily in males which have high levels of circulating androgens in the serum; females are usually asymptomatic. Indeed, the polyglutamine-expanded AR is converted to a neurotoxic species upon binding to androgens. The mechanisms through which androgen binding triggers the disease are under investigation. Although several therapeutic strategies have been proposed to date, there is currently no effective therapy to arrest or delay disease progression in patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pennuto</LastName><ForeName>Maria</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8634-0767</Identifier><AffiliationInfo><Affiliation>Dulbecco Telethon Institute Lab of Neurodegenerative Diseases, Centre for Integrative Biology (CIBIO), University of Trento, Via Sommarive 9, 38123, Trento, Italy. MPennuto@Dti.Telethon.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gozes</LastName><ForeName>Illana</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Lily and Avraham Gildor Chair for the Investigation of Growth Factors, Elton Laboratory for Neuroendocrinology, Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Adams Super Center for Brain Studies and Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, 69978, Israel. igozes@post.tau.ac.il.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D054711">Introductory Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>02</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Mol Neurosci</MedlineTA><NlmUniqueID>9002991</NlmUniqueID><ISSNLinking>0895-8696</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D055534" MajorTopicYN="N">Bulbo-Spinal Atrophy, X-Linked</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26875173</ArticleId><ArticleId IdType="doi">10.1007/s12031-016-0720-0</ArticleId><ArticleId IdType="pii">10.1007/s12031-016-0720-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Mol Neurosci. 2016 Mar;58(3):343-7</Citation><ArticleIdList><ArticleId IdType="pubmed">26563449</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuromuscul Disord. 2015 Oct;25(10):802-12</Citation><ArticleIdList><ArticleId IdType="pubmed">26206601</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Neurosci. 2016 Mar;58(3):330-4</Citation><ArticleIdList><ArticleId IdType="pubmed">26572533</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Neurosci. 2016 Mar;58(3):321-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26482145</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Neurosci. 2016 Mar;58(3):317-20</Citation><ArticleIdList><ArticleId IdType="pubmed">26547319</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Neurosci. 2016 Mar;58(3):365-73</Citation><ArticleIdList><ArticleId IdType="pubmed">26614347</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Neurosci. 2016 Mar;58(3):379-87</Citation><ArticleIdList><ArticleId IdType="pubmed">26572537</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Neurosci. 2016 Mar;58(3):374-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26691331</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Neurosci. 2016 Mar;58(3):348-64</Citation><ArticleIdList><ArticleId IdType="pubmed">26572535</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Neurosci. 2016 Mar;58(3):394-400</Citation><ArticleIdList><ArticleId IdType="pubmed">26744358</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Neurosci. 2016 Mar;58(3):388-93</Citation><ArticleIdList><ArticleId IdType="pubmed">26585990</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>